Neurofilaments in blood is a new promising preclinical biomarker for the screening of natural scrapie in sheep

Henrik Zetterberg¹,²,³,⁴, Elena Bozzetta⁵, Alessandra Favole⁶, Cristiano Corona⁵, Maria Concetta Cavarretta⁵, Francesco Ingravalle⁵, Kaj Blennow¹,², Maurizio Pocchiari⁶, Daniela Meloni⁴,*

¹ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, ² Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, ³ Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, United Kingdom, ⁴ UK Dementia Research Institute at UCL, University College London, London, United Kingdom, ⁵ Istituto zooprofilattico del Piemonte Liguria e Valle d’Aosta, Turin, Italy, ⁶ Department of Neuroscience, Istituto Superiore di Sanità, Roma, Italy

* daniela.meloni@izstol.it

Abstract

Scrapie is a fatal neurodegenerative disease of sheep and goats belonging to the group of Transmissible Spongiform Encephalopathy or prion diseases. The EU has adopted mandatory measures for scrapie surveillance to safeguard public and animal health because it is highly contagious and might decimate all genetic susceptible animals in affected flocks. Definite diagnosis of scrapie relies on the detection of the pathological prion protein in brain tissues and there are still no blood biomarkers available for making diagnosis in living animals that can be used for the screening of sheep in scrapie-affected flocks. Neurofilament light (NfL) protein, a valid biomarker for neuronal and axonal damages, can now be easily measured in blood by the ultra-sensitive single molecule array (Simoa) technology. Recent work reported that serum NfL is increased in neurodegenerative diseases, including human prion diseases, but no data are available for scrapie or other animal prion diseases. Here, we found that the median serum NfL concentration in scrapie animals (56.2, IQR 42.2–84.8, n = 9) was more than 15 times higher (p = 0.00084) than that found in control samples (3.4, IQR 3.0–26.3, n = 11). Moreover, serum NfL concentration in scrapie sheep with clinical signs (n = 2; 75.3, 15.7 pg/ml) did not significantly (p = 0.541; t-test) differ from scrapie animals without clinical signs (n = 7; 61.0, 10.7 pg/ml). The receiver operating characteristic (ROC) curve analysis estimated the cut-off value of 31 pg/ml serum NfL for distinguishing scrapie-infected sheep from controls. The application of this cut-off value gives an accuracy of the test of 95% (percent error of 5.23%). These data indicate that the Simoa test for serum NfL might be a useful screening method for detecting preclinical scrapie in living sheep. Finally, the preliminary data reported here need confirmation in large and more structured studies.
from the Swedish Research Council (2018-02532), the European Research Council (681712), Swedish State Support for Clinical Research (ALFGBG-720931), and the UK Dementia Research Institute at UCL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** KB has served as a consultant or at advisory boards for Avon, Biogen, CogRx, Lilly, MagQu, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper. HZ has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Biogen and Abecure, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper. MP is a member of the scientific advisory boards for Ferring Pharmaceuticals and the CNCCS (Collezione Nazionale di Composti Chimici e Centro Screening) Consortium (Pomezia, Italy), and vice-president of the Board of Director for the Fondazione Cellule Staminali (Terni, Italy), all unrelated to the work presented in this paper. The other authors have declared no competing interests. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

**Introduction**

Transmissible spongiform encephalopathy (TSE) or prion diseases are a group of fatal progressive neurodegenerative pathologies of humans and animals. Bovine spongiform encephalopathy (BSE), scrapie of sheep and goats, and Creutzfeld–Jakob disease (CJD) of humans are among the most notable TSE diseases [1]. BSE has been unequivocally linked to the appearance of variant CJD in humans, while scrapie, an endemic disease in Europe for >200 years, has never been convincingly associated with any form of human TSE diseases [2,3], apart from recent data on the experimental transmission of scrapie to humanized mice [4] or nonhuman primates [5,6].

Since 2002, EU adopted mandatory measures for the TSE surveillance on small ruminants to safeguard public and animal health. Each Member State (MS) has to carry out an annual monitoring program for TSE diseases based on active (testing on regularly slaughtered and risk animals) and passive (testing on clinical suspected cases) surveillances. More than 9 million small ruminants, 2/3 are sheep, have been tested as part of the official EU TSE surveillance (Reg. EU 999/2001) by one of the EU-approved tests and the number of tested animals in 2017 had an 8.7% (34,623 samples) increase compared with 2016.

TSEs are characterized by the misfolding of the host-encoded prion protein (PrPSc) in its abnormal isoform (PrPSc). The conformation of PrPSc differs from that of PrPc in the amount of β-sheets leading to its tendency for aggregation and accounting for its partial proteinase K (PK) resistance [7]. PrPSc deposits and accumulates in great amount in the central nervous tissue (CNS) and, to a lesser extent, in peripheral tissues such as the lymphoreticular system (LRS) and other tissues or body fluids [8]. Most methods currently applied for the diagnosis of animal TSE diseases, including EU-approved ELISA tests and confirmatory western blots exploit the PK resistance of PrPSc and its great accumulation in the brain. Because the EU-approved tests need to be performed on CNS tissues, it is practically impossible to achieve a definite diagnosis of TSE disease in living animals. The detection of PrPSc in body fluids has been unsuccessful for a long time and, despite some recent promising results [9], the development of suitable tests for screening large numbers of animals is still lagging behind. Misfolded protein amplification techniques (Protein Misfolding Cyclic Amplification technology, PMCA, and Real-Time Quaking Induced Conversion assay, RT-QuIC) are able to amplify minute amounts of PrPSc in cerebrospinal fluid (CSF) and olfactory mucosa [9], and have been recently included in the international diagnostic criteria for sporadic CJD [10]. Such approaches, however, are of little utility for the screening of scrapie: lumbar puncture is a relatively invasive procedure and nasal brushing for taking the olfactory mucosa is impracticable in sheep for anatomical reasons. Finally, these tests are still not validated for the detection of PrPSc in blood despite that encouraging results have been obtained in some human and animal TSE diseases [11–14].

Recently, ultrasensitive immunoassay techniques such as single molecule array (Simoa, Quanterix, MA, USA) have enabled the reliable quantification of very low concentrations of proteins in body fluids [15], including neurofilament light (NFL) protein in blood samples [16]. NFL is a 68kDa cytoskeletal intermediate filament protein that is expressed in neuronal axons and released into the cerebrospinal fluid (CSF) and blood when neurons are injured [17], providing a valuable new biomarker with emerging diagnostic, prognostic, and therapy-monitoring roles in neurodegenerative and other human neurological diseases [17].

Here, we explore for the first time the value of serum NFL as marker for neuronal degeneration in sheep with natural scrapie disease. This is easily achievable because the amino acid sequence of the core domain of NFL, against which antibodies in the Simoa assay were developed, is 100% conserved in the animal kingdom [17].
Materials and methods

Animal cohort

The twenty Italian sheep included in the study were selected in the context of the scrapie surveillance system in Italy. Nine were field scrapie cases and 11 were healthy animals. Blood samples were collected just before slaughtering. The health status of the animals was assessed by the local veterinary service. Prion protein gene (PRNP) genotype defined on the basis of polymorphisms at codons 136, 154 and 171 was performed as described [18].

Diagnosis of scrapie

Diagnosis of scrapie was performed on the medulla oblongata firstly by an enzyme-linked immunosorbent assay (ELISA)-based method (IDEXX HerdChek BSE-scrapie antigen test kit EIA rapid test—IDEXX Laboratories, Westbrook, ME, USA) followed by a confirmatory western blot method. The CEA internal western blot technique has been described elsewhere [19]. These methods represent the gold standard techniques for making the diagnosis of scrapie in SNC samples [20–21].

NfL measurement

Serum NfL concentration in sheep sera was measured using an in house Simoa assay on an HD-1 Analyzer (Quanterix, Lexington, MA), as previously described in detail [16]. Board-certified laboratory technicians, blind to clinical and laboratory data, performed the measurements. Samples were measured in singlicates with a 4-fold dilution. Two quality control (QC) samples were analyzed in duplicates in the beginning and end of each run. For a QC sample with a concentration 11.3 pg/mL, repeatability was 4.0%. For a QC sample with a concentration 42.6 pg/mL, repeatability was 1.8%.

Statistical analyses

Statistical analysis was performed using GraphPad Prism 5.0 software. Biomarker distributions were graphed as box plots and comparisons between groups were carried out by the non-parametric two-tailed unpaired Mann-Whitney U test with significance level of 5%. The efficiency of each biomarker was assessed by the receiver operating characteristic (ROC) curve analyses. Nonparametric ROC curves analyzed sheep with scrapie vs controls. The area under the ROC curve (AUC) and its 95% confidence interval (95% CI) indicate diagnostic efficiency. The accuracy of the test with the percent error is reported.

Ethics statement

All animals used in this work were farm sheep slaughtered in official abattoirs and samples were taken in compliance with EU mandatory measures for the for the prevention, control and eradication of scrapie and other transmissible spongiform Encephalopathies (REGULATION (EC) No 999/2001, OJ L 147, 31.5.2001, p. 1).

Results

The veterinary of the local health service reported that 2 of the 20 sheep used in this experiment showed clinical signs of scrapie consisting of proprioceptive deficit and low body condition score. The other 18 sheep were clinically unremarkable (Table 1). The ELISA test detected PrP Sc in 9 sheep, including the 2 samples from animals with clinical signs. Western blot analysis confirmed the presence of PrP Sc in all 9 samples that were positive in the ELISA test. The
other 11 sheep were negative at both the preliminary ELISA test and the confirmatory western blotting analysis. There was no significant difference (p = 0.5913; Fisher’s exact test) in the M/F distribution between scrapie (1/8) and control (3/8) sheep. All sheep carried the ARQ/ARQ genotype of the prion protein gene.

The concentration of serum NfL in each sample is shown in Table 1. The median serum NfL concentration in scrapie animals was more than 15 times higher than that found in control samples (Table 1). However, the serum NfL concentration in scrapie sheep with clinical signs (n = 2; 75.3, 15.7 pg/ml) did not significantly (p = 0.541; t-test) differ from scrapie animals without clinical signs (n = 7; 61.0, 10.7 pg/ml). It is of note that all control animals but one had serum NfL concentration well below the lowest level of scrapie sheep (Table 1 and Fig 1) suggesting that this test is valuable for making an accurate screening of scrapie in living sheep The ROC curve (Table 1 and Fig 2) provided the cut-off value of 31 pg/ml serum NfL for distinguishing scrapie from control sheep with an accuracy of the test of 95% (percent error, 5.26%). Considering only animals with no clinical signs of scrapie (n = 18), the accuracy of the test for the preclinical identification of scrapie-infected sheep was 94.4% (percent error, 5.9%).

**Discussion**

Our data show that scrapie-affected sheep have significantly higher levels of serum NfL than control sheep, similarly to what has been reported for human TSEs [22–25], other patients affected by degenerative or inflammatory diseases of the nervous system [17], and experimental animal models of neurodegenerative diseases [26–29]. These results confirm the importance of the Simoa test to quantify small amount of NfL in blood and other body fluids and the
The preliminary data reported here need, however, to be confirmed in large and more structured studies before the introduction of the Simoa test for measuring serum NfL in sheep.

Fig 1. Concentrations of serum NfL in scrapie-affected sheep (circles) and controls (squares). The central bars indicate median values; upper and bottom bars indicate interquartile ranges. The top dashed line is the cut-off value of 31 pg/ml of serum NfL, obtained from the ROC curve analyses (Fig 2) that gives 90.9% specificity and 100% sensitivity, while the bottom dashed line indicates the lowest limit of detection (LLOD) of NfL (0.62 pg/ml).

https://doi.org/10.1371/journal.pone.0226697.g001
Comparing scrapie with healthy controls likely overestimated the diagnostic accuracy reported in this study and more appropriate field studies with a large cohort of animals affected by various pathologies mimicking scrapie (e.g. coenurosis, leptospirosis, etc.) are needed for a better estimate of sensitivity and specificity in recognizing scrapie disease. The scrapie negative sample (Table 1 and Fig 1) with high serum NfL concentration was an unexpected result although it might be related to neuroaxonal injury in asymptomatic or preclinical inflammatory, infectious, or traumatic neurological conditions [38]. Finally, in this study all samples were taken from sheep carrying the same PRNP genotype (ARQ/ARQ) and it is critical to extend this analysis to blood samples taken from other genotypes. It is well established that PRNP genotypes in sheep influence susceptibility to scrapie and likely determine different clinical and pathological phenotypes [39].

In conclusion, we believe that the improved sensitivity of the digital immunoassay (Simoa) over previously reported approaches will translate into preclinical diagnostic benefits of paramount importance for managing scrapie disease in sheep and possibly other animal prion diseases.

**Author Contributions**

**Conceptualization:** Henrik Zetterberg, Elena Bozzetta, Daniela Meloni.
Data curation: Henrik Zetterberg, Elena Bozzetta, Cristiano Corona, Daniela Meloni.
Formal analysis: Henrik Zetterberg, Maurizio Pocchiari.
Funding acquisition: Henrik Zetterberg, Kaj Blennow.
Investigation: Henrik Zetterberg, Alessandra Favole, Cristiano Corona, Maria Concetta Cavarretta, Francesco Ingravalle, Daniela Meloni.
Methodology: Henrik Zetterberg, Alessandra Favole, Maria Concetta Cavarretta, Francesco Ingravalle, Daniela Meloni.
Project administration: Henrik Zetterberg, Daniela Meloni.
Resources: Henrik Zetterberg, Cristiano Corona, Kaj Blennow, Daniela Meloni.
Supervision: Henrik Zetterberg, Elena Bozzetta, Daniela Meloni.
Visualization: Henrik Zetterberg, Daniela Meloni.
Writing – original draft: Henrik Zetterberg, Daniela Meloni.
Writing – review & editing: Henrik Zetterberg, Elena Bozzetta, Cristiano Corona, Kaj Blennow, Maurizio Pocchiari, Daniela Meloni.

References
1. Johnson RT. Prion diseases. Lancet Neurol. 2005; 4:635–42. https://doi.org/10.1016/S1474-4422(05)70192-7 PMID: 16168932
2. Houston F, Andréoletti O. Animal prion diseases: the risks to human health. Brain Pathol. 2019; 29:248–62. https://doi.org/10.1111/bpa.12696 PMID: 30588682
3. Houston F, Andréoletti O. The zoonotic potential of animal prion diseases. Handb Clin Neurol. 2018; 153:447–62. https://doi.org/10.1016/B978-0-444-63945-5.00025-8 PMID: 29887151
4. Cassard H, Torres JM, Lacroux C, Douet JY, Benestad SL, Lantier F, et al. Evidence for zoonotic potential of ovine scrapie prions. Nat Commun. 2014; 5:5821. https://doi.org/10.1038/ncomms5821 PMID: 25510416
5. Baker HF, Ridley RM, Wells GA. Experimental transmission of BSE and scrapie to the common marmoset. Vet Rec. 1993; 132:403–6. https://doi.org/10.1136/vr.132.16.403 PMID: 8488658
6. Comoy EE, Mikol J, Luccantoni-Freire S, Correia E, Lescoutra-Etchegary N, Durand V, et al. Transmission of scrapie prions to primates after an extended silent incubation period. Sci Rep. 2015; 5:11573. https://doi.org/10.1038/srep11573 PMID: 26123044
7. Gill AC, Castle AR. The cellular and pathologic prion protein. Handb Clin Neurol. 2018; 153:21–44. https://doi.org/10.1016/B978-0-444-63945-5.00002-7 PMID: 29887138
8. Chianini F, Cosseddu GM, Steele P, Hamilton S, Hawthorn J, Siso S, et al. Correlation between infectivity and disease associated prion protein in the nervous system and selected edible tissues of naturally affected scrapie sheep. PLoS One. 2015; 10:e0122785. https://doi.org/10.1371/journal.pone.0122785 PMID: 25807559
9. Zanusso G, Monaco S, Pocchiari M, Caughey B. Advanced tests for early and accurate diagnosis of Creutzfeldt-Jakob disease. Nat Rev Neurol. 2016; 12:325–33. https://doi.org/10.1038/nrneurol.2016.65 PMID: 27174240
10. Mackenzie G, Will R. Creutzfeldt-Jakob disease: recent developments. F1000Res. 2017; 6:2053. https://doi.org/10.12688/f1000research.12681.1 PMID: 29225787
11. Kramm C, Pritzkow S, Lyon A, Nichols T, Morales R, Soto C. Detection of Prions in Blood of Cervids at the Asymptomatic Stage of Chronic Wasting Disease. Sci Rep. 2017; 7:17241. https://doi.org/10.1038/s41598-017-17090-x PMID: 29222449
12. Concha-Marambio L, Pritzkow S, Moda F, Tagliavini F, Ironside JW, Schulz PE, et al. Detection of prions in blood from patients with variant Creutzfeldt-Jakob disease. Sci Transl Med. 2016; 8:370ra183. https://doi.org/10.1126/scitranslmed.aaf6186 PMID: 28003548
13. Bougard D, Brandel JP, Belondrade M, Béringer V, Segarra C, Fleury H, et al. Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Sci Transl Med. 2016; 8:370ra182. https://doi.org/10.1126/scitranslmed.aag1257 PMID: 28003547
14. Castillo J, Saá P, Soto C. Detection of prions in blood. Nat Med. 2005; 11:982–5. https://doi.org/10.1038/nm1286 PMID: 16127436

15. Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010; 28:595–9. https://doi.org/10.1038/nbt.1641 PMID: 20495550

16. Gissiére M, Price RW, Andreaussen U, Norgren N, Nilsson S, Hagberg L, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 2015; 3:315–340. https://doi.org/10.1016/j.ebiom.2015.11.036 PMID: 26870824

17. Khali M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as promising biomarkers in neurological disorders. Nat Rev Neurol 2018; 14:577–89. https://doi.org/10.1038/s41582-018-0058-z PMID: 30171200

18. Acutis PL, Sbaiz L, Verburg F, Riina MV, Ru G, Moda G, et al. Low frequency of the scrapie resistance-associated allele and presence of lysine-171 allele of the prion gene in Italian Biellese ovine breed. J Gen Virol. 2004; 85:3165–72. https://doi.org/10.1099/vir.0.80053-0 PMID: 15448380

19. Mazza M, Iulini B, Vaccari G, Acutis PL, Martucci F, Esposito E, et al. Co-existence of classical scrapie and Nor98 in a sheep from an Italian outbreak. Res Vet Sci. 2010; 88:478–85. https://doi.org/10.1016/j.rvsc.2009.11.015 PMID: 20031179

20. European Food Safety Authority. Scientific report of the European Food Safety Authority on the evaluation of rapid post mortem TSE tests intended for small ruminants. Adopted on 17 May 2005. EFSA J 2005; 31:1–17. Question No. EFSA-Q-2003-084.

21. European Food Safety Authority. Scientific Opinion on the evaluation of new TSE rapid tests submitted in the framework of the Commission Call for expression of interest 2007/S204-247339. Adopted on 19 April 2012. Question No EFSA-Q-2008-327/455/456/457/458/459/460.

22. Staffaroni AM, Kramer AO, Casey M, Kang H, Rojas JC, Orrú CD, et al. Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. JAMA Neurol. 2019 May 6 https://doi.org/10.1001/jamaneurol.2019.1071 [Epub ahead of print] PMID: 31058916

23. Thompson AGB, Luk C, Heslegrave AJ, Zetterberg H, Mead SH, Collinge J, et al. Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. J Neurol Neurosurg Psychiatry. 2018; 89:955–61. https://doi.org/10.1136/jnnp-2017-317793 PMID: 29487167

24. Kovacs GG, Andreaussen U, Liman V, Regelsberger G, Lutz MI, Danics K, et al. Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuro-pathology-based cohort. Eur J Neurol. 2017; 24:1326–e77. https://doi.org/10.1111/ene.13389 PMID: 28816001

25. Steinacker P, Blennow K, Hallgebauer S, Shi S, Ruf V, Oecld P, et al. Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep. 2016; 6:38737. https://doi.org/10.1038/srep38737 PMID: 27929120

26. Lewczuk P, Riederer P, O’Bryant SE, Verbeek K, Wild EJ, Zetterberg H, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. 2018; 19:244–328. https://doi.org/10.1080/15622975.2017.1375556 PMID: 29076399

27. Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaesser SA, et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron. 2016; 91:56–66. https://doi.org/10.1016/j.neuron.2016.05.018 PMID: 27292537

28. Clement A, Mitchelmore C, Andersson DR, Asuni AA. Cerebrospinal fluid neurofilament light chain as a biomarker of neurodegeneration in the Tg4510 and MitoPark mouse models. Neuroscience. 2017; 354:101–109. https://doi.org/10.1016/j.neuroscience.2017.04.030 PMID: 28461218

29. Soylu-Kucharz R, Sandelius Å, Sjögren M, Blennow K, Wild EJ, Zetterberg H, et al. Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice. Sci Rep. 2017; 7:14114. https://doi.org/10.1038/s41598-017-14179-1 PMID: 29074982

30. Zerr I, Schmitz M, Karch A, Villar-Piqué A, Kanata E, Golanska E, et al. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimers Dement. 2018; 14:751–763. https://doi.org/10.1016/j.jalz.2017.12.006 PMID: 29391125

31. Abu-Rumeileh S, Capellari S, Stanzani-Maserati M, Polischi B, Martinelli P, Caroppi P, et al. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimers Res Ther. 2018; 10:3. https://doi.org/10.1186/s13195-017-0331-1 PMID: 29368621
32. Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology. 2005; 64:1586–91. https://doi.org/10.1212/01.WNL.0000160117.56690.B2 PMID: 15883321

33. Ligios C, Viglietti A, Carta P, Dexter G, Agrimi U, Simmons MM. Clinicopathological findings in sheep from Sardinia showing neurological signs of disease. Vet Rec. 2004; 154:365–70. https://doi.org/10.1136/vr.154.12.365 PMID: 15074327

34. Polizopoulou SZ, Giadinis DN, Papahristou A, Papaioannou N. Neurological diseases of small ruminants in Greece: a retrospective study in 114 flocks. Acta Veterinaria-Belograd. 2016: 66:160–71.

35. Llorens F, Barrio T, Correia À, Villar-Piqué A, Thüne K, Lange P, et al. Cerebrospinal Fluid Prion Disease Biomarkers in Pre-clinical and Clinical Naturally Occurring Scrapie. Mol Neurobiol. 2018; 55:8586–8591. https://doi.org/10.1007/s12035-018-1014-z PMID: 29572672

36. Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med. 2019; 25:277–283. https://doi.org/10.1038/s41591-018-0304-3 PMID: 30664784

37. van der Ende EL, Meeter LH, Poos JM, Panman JL, Jiskoot LC, Dopper EGP, et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol. 2019; 18:1103–1111. https://doi.org/10.1016/S1474-4422(19)30354-0 PMID: 31701893

38. Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol. 2019; 76:1035–1048.

39. Greenlee JJ. Review: Update on Classical and Atypical Scrapie in Sheep and Goats. Vet Pathol. 2019; 56:6–16. https://doi.org/10.1177/0300985818794247 PMID: 30200819